Finding treatments and therapy for rare retinal diseases.

Finding treatments and therapy for rare retinal diseases.

Illustrated icon of a DNA molecule

About Odylia

Illustrated icon of a gearwheel spinning

Our Path

Illustrated icon of a scientists' beaker with a solution in it

Resources

Illustrated icon of an atom

Consortium

Our path to finding cures

We promote treatments of rare eye diseases from lab to clinic

What we do

Odylia Therapeutics is a non-profit corporation working to bring treatments for rare eye disease from the lab into humans using genetic therapies.  Today, there are more than 300 known genetic forms of Inherited Retinal Disease (IRD) that lead to blindness, with some of these interfering with other sensory mechanisms like hearing and balance.  Most are extremely rare, impacting less than one in a million people worldwide.

Why we exist

Although pre-clinical proof-of-concept treatments exist for some of these diseases, because they are so rare, there is little commercial interest in them.  Odylia was formed to find a way to move these potential therapies into clinical trials to protect and restore the vision of those going blind.

Why we exist

Although pre-clinical proof-of-concept treatments exist for some of these diseases, because they are so rare, there is little commercial interest in them.  Odylia was formed to find a way to move these potential therapies into clinical trials to protect and restore the vision of those going blind.

Latest news

Stay up-to-date with our research and clinical trials

Questions? We’re here to help!